WikiMD is world's largest health encyclopedia with
28,557 pages, 3,991,937 edits & 34,290,934 views.
Ramucirumab
Information about Ramucirumab
Ramucirumab is a human monoclonal antibody to the vascular endothelial growth factor (VEGF) receptor 2 and is an antiangiogenesis agent used in the therapy of advanced colorectal, gastric and lung cancers.
Liver safety of Ramucirumab
Ramucirumab has not been linked to serum enzyme elevations during therapy or to instances of idiosyncratic acute liver injury, but has been reported to worsen liver failure in patients with decompensated cirrhosis (Child Class B or C).
Mechanism of action of Ramucirumab
Ramucirumab (ra" mue sir' ue mab) is a recombinant human monoclonal IgG1 antibody to the vascular endothelial growth factor receptor 2. Receptors for VEGF are present on endothelial cells, and the engagement of VEGF with these receptors promotes cell proliferation and angiogenesis. Inhibition of VEGF receptor 2 signaling decreases formation of new blood vessels, which plays an important role in growth and spread of cancer cells. When used in combination with other antineoplastic agents, ramucirumab has been shown to extend progression-free and overall survival in several forms of advanced cancer.
FDA approval information for Ramucirumab
Ramucirumab was approved in the United States in 2014 for use in refractory, advanced gastric and metastatic non-small cell lung cancer. Indications were broadened in 2015 to include metastatic colorectal cancer. Ramucirumab is available in solution in single use vials of 100 mg in 10 mL or 500 mg in 50 mL (10 mg/mL) under the brand name Cyramza.
Dosage and administration for Ramucirumab
The typical dose is 8 or 10 mg/kg intravenously at intervals of every 2 or 3 weeks based upon indication the other antineoplastic agents used in combination. Ramucirumab has significant adverse side effects.
Side effects of Ramucirumab
Common adverse events include diarrhea, fatigue, anorexia, epistasis, hypertension, neutropenia, and stomatitis. Uncommon, but potentially severe adverse events include arterial thromboembolic events, severe hypertension, infusion reactions, impaired wound healing, worsening of cirrhosis, thyroid dysfunction, renal dysfunction including proteinuria and nephrotic syndrome, and embryofetal toxicity.
Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ
Cost and Coupons - Ramucirumab
- GoodRx compare cost & coupons for Ramucirumab
- Find the lowest cost of Ramucirumab
- Search for Coupons for Ramucirumab
Reviews for Ramucirumab
Learn more about Ramucirumab
Latest research (Pubmed)
External links
WikiMD needs you!
This WikiMD article Ramucirumab is a stub.
If you are a healthcare professional familiar with the topic Ramucirumab, or
A subject matter expert or authority on Ramucirumab, you can help us.
About | Mission | Paid editors welcome!
| Ramucirumab is part of WikiMD's Physician reviewed^ articles available 4free, 4all, 4ever! |
|---|
| Medicine: Health - Encyclopedia - Topics - Diseases - Cancer - Rare diseases - Random Page Navigation: Drugs - Wellness - Obesity - Diet - Ketogenic diet - W8MD weight loss diet - Editors: Recently Edited Pages - Alphabetical Order - Sponsors - USMLE The content on or accessible through WikiMD is for informational purposes only. WikiMD is not a substitute for professional medical advice. ^See full Disclaimers |
 Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP* |
